Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

Walgreen's prescription drug sales rose 24.1% for the three months (ended Feb. 28) and 24.4% for the first six months of fiscal 1989. "Third party prescription plans are becoming an increasing percentage of the pharmacy business," the drug chain noted in its sales and earnings report released April 12. Walgreen said it plans to expand its on-line pharmacy computers in anticipation of a sharp rise Rx drug sales resulting from the Medicare Catastrophic Care Act. To date, the firm has installed satellite antennas in 590 of its 1,449 drugstores in order to reduce transmission time for claims processing. Walgreen reported a 9.3% sales increase in the second quarter to $ 1.48 bil. Six month sales were up 9% to $ 2.7 bil. For six months, drugstore sales were up 12%, Walgreen said. Volume for drug stores open at least one year rose 8.8% in the six-month period. Net earnings increased 20.6% to $ 57.3 mil. for the quarter and were up 23.7% to $ 82 mil. for the six month period. Chart omitted.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts